Mylan Launches First Bioequivalent Alternative to GSK's Inhaler

Jun 10, 2015

Mylan has has launched the first bioequivalent alternative to GlaxoSmithKline's Seretide Evohaler under the brand name Sirdupla, in the UK.

The product is being manufactured by 3M Drug Delivery Systems. 3M will fill, assemble and package Sirdupla at 3M's manufacturing facility in Loughborough, UK.

Mylan's Sirdupla is a pressurized metered-dose inhaler indicated to help treat or prevent symptoms of asthma in adults 18 years of age and older.

Read the 3M press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments